Neutropenic Fever Antibiotics

Obtain blood cultures from each central-line lumen plus one peripheral culture; if no central line is present, obtain two peripheral cultures. Direct additional cultures and imaging to a clinical focus; chest radiograph and chest CT are indicated by symptoms or examination findings. These diagnostic steps must not postpone empiric antibacterial therapy, which should ideally start within 1 hour of fever onset. PubMed+2PubMedManagement and Preventive Measures for Febrile Neutropenia - PMCIDSASkin and Soft Tissue Infections - IDSAacpjournalsManagement of Patients With Fever and Neutropenia Through the ...

At presentation, classify the patient as high risk if profound neutropenia (ANC <100 cells/µL) is anticipated for >7 days or if the MASCC score is <21. A MASCC score ≥21 supports low-risk classification only when the patient has few comorbidities and is clinically stable; expected neutropenia <7 days is another low-risk feature. IDSA+2IDSASkin and Soft Tissue Infections - IDSAPubMedFebrile Neutropenia - StatPearls - NCBI BookshelfPubMedManagement and Preventive Measures for Febrile Neutropenia - PMC

Treat sepsis or septic shock using the local sepsis protocol while delivering empiric antipseudomonal therapy. In critically ill neutropenic patients, select antibiotics using the initial clinical assessment, prior microbiology, and hospital ecology; consideration of an aminoglycoside in addition to the beta-lactam has supporting evidence in this setting. PubMed+1PubMedThe Dutch Working Party on Antibiotic Policy (SWAB) Recommendations for the Diagnosis and Management of Febrile Neutropenia in Patients with CancerPubMedThe strategy of antibiotic use in critically ill neutropenic patients - PMC

For high-risk febrile neutropenia without a defined resistant-pathogen indication, start IV monotherapy with cefepime, piperacillin-tazobactam, meropenem, or imipenem-cilastatin. Beta-lactam monotherapy with cefepime, piperacillin-tazobactam, or a carbapenem has broadly comparable efficacy in this setting. PubMed+1PubMedManagement and Preventive Measures for Febrile Neutropenia - PMCPubMedThe strategy of antibiotic use in critically ill neutropenic patients - PMC

A dosing framework for adults with fever of unknown origin and high-risk neutropenia is cefepime 2 g IV every 8 hours, piperacillin-tazobactam 4.5 g IV every 6 hours, meropenem 1 g IV every 8 hours, or imipenem-cilastatin 500/500 mg IV every 6 hours. These regimens require patient-specific adjustment when renal dysfunction is present; this source does not specify adjustment schedules. PubMedPubMedThe Dutch Working Party on Antibiotic Policy (SWAB) Recommendations for the Diagnosis and Management of Febrile Neutropenia in Patients with Cancer

Choose a carbapenem rather than a narrower antipseudomonal beta-lactam when the patient has known colonization or prior infection with resistant Gram-negative bacteria, local epidemiology indicates a high likelihood of resistance, a resistant pathogen is suspected from the infection site, or the patient has a severe clinical presentation. Contemporary recommendations emphasize this individualized approach rather than a uniform empiric regimen. ScienceDirect+1ScienceDirectEmpirical and targeted antimicrobial therapy in patients with febrile neutropenia and haematological malignancy or after haematopoietic cell transplantation: recommendations from the 10th European Conference on Infections in LeukaemiaPubMedThe strategy of antibiotic use in critically ill neutropenic patients - PMC

Do not add vancomycin routinely to initial antipseudomonal beta-lactam therapy. Reserve it for suspected methicillin-resistant Gram-positive infection or severe sepsis/septic shock; beta-lactam monotherapy trials have not shown a general benefit from routine vancomycin addition. PubMed+1PubMedThe strategy of antibiotic use in critically ill neutropenic patients - PMCNatureClinical profile, treatment, and outcomes of febrile neutropenia in hematologic disorders: a look at 30-day mortality predictors | Scientific Reports

If initial combination therapy included vancomycin or another secondary agent, discontinue the added agent after 24 to 72 hours when there are no new clinical signs and cultures do not identify an organism requiring that coverage. This reduces unnecessary glycopeptide exposure, including selection pressure for vancomycin-resistant enterococci and nephrotoxicity risk. ScienceDirect+1ScienceDirectFebrile Neutropenia - an overview | ScienceDirect TopicsPubMedThe strategy of antibiotic use in critically ill neutropenic patients - PMC

In critically ill neutropenic patients, an aminoglycoside may be considered with the antipseudomonal beta-lactam as part of an individualized strategy. The decision should be driven by severity, the patient's prior bacterial history, and local ecology rather than by neutropenia alone. PubMedPubMedThe strategy of antibiotic use in critically ill neutropenic patients - PMC

A patient with MASCC score ≥21, anticipated neutropenia <7 days, few comorbidities, and clinical stability may be considered for oral treatment rather than routine inpatient IV therapy. Risk categorization should not override bedside concern: even a nominally low-risk patient may warrant initial admission and IV antibiotics for observation. IDSA+1IDSASkin and Soft Tissue Infections - IDSAPubMedManagement and Preventive Measures for Febrile Neutropenia - PMC

A studied oral regimen is ciprofloxacin 750 mg every 12 hours plus amoxicillin-clavulanate 500/175 mg every 8 hours for 5 days. Another recommendation for standard-risk neutropenia with a high MASCC score lists amoxicillin-clavulanate 500/125 mg orally as part of low-risk treatment, but the excerpt does not provide its complete companion-regimen details. Nature+1NatureOral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study | British Journal of CancerPubMedThe Dutch Working Party on Antibiotic Policy (SWAB) Recommendations for the Diagnosis and Management of Febrile Neutropenia in Patients with Cancer

Outpatient assignment requires an explicit safety plan because low-risk outpatient trials have still reported subsequent hospitalization. In one prospective trial of an unselected outpatient population that included acute leukemia, 21% required hospitalization and mortality was 4%; that population does not establish safety for broad outpatient use. NatureNatureOral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study | British Journal of Cancer

For high-risk patients with prolonged neutropenia who remain persistently febrile despite broad-spectrum antibacterial therapy, initiate empiric antifungal therapy after reassessing for a source and nonfungal causes. Recommended options include a lipid formulation of amphotericin B, an echinocandin such as caspofungin or micafungin, or voriconazole. IDSAIDSAIDSA 2016 Clinical Practice Guideline Update for the Diagnosis and ...

Persistent fever after 4 to 7 days of broad-spectrum antibacterial therapy is a commonly cited trigger for empiric antifungal coverage in high-risk patients when fungal infection is suspected. Do not give empiric antifungal therapy solely for persistent fever when neutropenia is expected to last <10 days unless clinical or diagnostic findings suggest invasive fungal infection. PubMed+1PubMedFebrile Neutropenia - StatPearls - NCBI BookshelfIDSAIDSA 2016 Clinical Practice Guideline Update for the Diagnosis and ...

In patients already receiving anti-Aspergillus prophylaxis, persistent fever is less likely to represent a fungal infection; evaluate nonfungal causes and consider breakthrough invasive fungal infection potentially resistant to the prophylactic agent before selecting antifungal therapy. IDSAIDSAIDSA 2016 Clinical Practice Guideline Update for the Diagnosis and ...

Reassess the empiric regimen after culture data and clinical evolution. Modify therapy for positive cultures, a newly identified focus, clinical deterioration, or resistant-organism recovery; when no resistant Gram-positive pathogen or syndrome is identified, withdraw empiric glycopeptide coverage rather than continuing it indefinitely. ScienceDirect+1ScienceDirectFebrile Neutropenia - an overview | ScienceDirect TopicsPubMedThe strategy of antibiotic use in critically ill neutropenic patients - PMC

For treated infection, antibacterial therapy may be continued until the infection has cleared or the ANC is at least 500 cells/mm3. If the treatment course is complete but neutropenia persists and all signs and symptoms of documented infection have resolved, oral fluoroquinolone prophylaxis may be resumed until marrow recovery in patients for whom prophylaxis is otherwise indicated. PubMedPubMedFebrile Neutropenia - StatPearls - NCBI Bookshelf

Antibacterial fluoroquinolone prophylaxis is recommended by cited guideline summaries for patients expected to be neutropenic for >7 days. This prevention decision is distinct from choosing treatment for a breakthrough febrile episode, which still requires prompt empiric broad-spectrum therapy. Wiley+1WileyTreatment of Febrile Neutropenia and Prophylaxis in Hematologic ...IDSAIDSA 2019 Clinical Practice Guideline Update for the Management ...